PubRank

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (VARIATION 2 SA)

Clinical Trial ID NCT03819790

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03819790

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 95.79
2 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 35.49
3 Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 2014 6.51
4 Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014 6.39
5 Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015 3.33
6 Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998 3.18
7 One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004 2.74
8 A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008 2.68
9 Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004 2.22
10 Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. Ann Intern Med 2015 2.09
11 Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. CMAJ 2010 1.85
12 Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014 1.44
13 Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004 1.37
14 Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci 2013 1.32
15 Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014 1.11
16 Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014 1.03
17 Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. Diabetes Care 2016 0.81
18 Temporal trends in cardiovascular disease risk factors among white, South Asian, Chinese and black groups in Ontario, Canada, 2001 to 2012: a population-based study. BMJ Open 2015 0.79
19 Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Diabetes Care 2016 0.75
20 Exp Clin Endocrinol Diabetes 2017 0.75
21 TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL. Can J Diabetes 2017 0.75
Next 100